The FDA has approved Wegovy HD, a once-weekly semaglutide 7.2 mg injection for adults with obesity. In the 72-week STEP UP trial, the higher dose produced 20.7% mean weight loss, with about one-third of participants achieving at least 25% weight loss. Novo Nordisk expects a US launch in April 2026.

What makes this approval more relevant than a routine label update is the clinical context around it. In a recent Diabetes Dialogue discussion, Diana Isaacs and Natalie Bellini described semaglutide 7.2 mg as another option for people who respond well to semaglutide 2.4 mg but still plateau and would benefit from additional weight loss. They also stressed that higher doses can bring more side effects, which makes individualization just as important as escalation.

That perspective may be the most important takeaway. Isaacs noted that obesity management may start to look more like treatment for hypertension or diabetes, where clinicians titrate therapy more carefully and may eventually need to step treatment down once patients reach a more appropriate range. Bellini added that this kind of weight loss would have seemed hard to imagine not long ago, and that newer agents are already changing expectations around what obesity treatment can achieve.

Another practical point is that the headline 20.7% result reflects the efficacy estimand, meaning the effect if participants stayed on treatment as planned. The treatment-regimen estimand was 18.7%, which still suggests a meaningful improvement and gives a more grounded view of how the drug performed when adherence issues are taken into account. That distinction helps keep the discussion useful rather than promotional.

Why This Matters

Semaglutide 7.2 mg does not change the broader story overnight, but it does give clinicians more room to tailor care for people who need more than 2.4 mg can provide. That makes this approval less about a bigger dose and more about a more flexible treatment pathway.

April 7, 2026 Update

Novo Nordisk announced today that Wegovy HD is now available nationwide in the United States. The company said self-paying adults prescribed Wegovy HD can expect a price of $399 per month. Patients new to the Wegovy savings offer or NovoCare Pharmacy can pay $199 per month for Wegovy 0.25 mg and 0.5 mg through June 30, 2026, then pay $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg after the introductory offer ends. Commercially insured patients may pay as little as $25 per month with the Wegovy savings offer. Novo Nordisk also said Wegovy HD is assembled and packaged at its Clayton, North Carolina facility.

Sources

Diabetes Dialogue Podcast
Novo Nordisk Press Release
Novo Nordisk Press Release for Update
Fierce Pharma Coverage